sglt2 inhibitors and glp-1 receptor agonists SGLT-2 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease empagliflozin glp-1 Use of Receptor

Your provider will work with you to develop a personalised treatment plan based on your individual needs and goals

An expert safety panel reviewed it and found it safe when formulations are made to be non-irritating

Modern liver-specific IGF-1 knockout studies have shown that local IGF-1 contributes substantially to tissue IGF1R activation, separate from the endocrine pool

MacEwan, TNF mediates the sustained activation of Nrf2 in human monocytes

Reducing human exposure to aflatoxins through enterosorption

Research published in Dermatologic Surgery demonstrated that subcutaneous delivery of bioactive peptides produced dermal tissue concentrations 4.2 higher than IM administration at 24 hours post-injection, with sustained elevation lasting 72+ hours